RxDoctor Payments Data

Mohannad Abu Omar, MD

Pulmonary Disease · Saint Joseph, MONPI 1598011694

Payments from drug & device makers

$4,812in general payments, 2019–2025

Across 64 payments — averaging $75.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Noah Medical Corporation$2K
  • Pulmonx Corporation$1K
  • Boston Scientific$461
  • Galvanize Therapeutics, Inc$264
  • AstraZeneca$229
  • Boehringer Ingelheim$146
  • plus $207 from 8 others

What the payments were for

  • Travel & lodging$2,72457%
  • Food & beverage$2,07743%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,812 in reported general payments places this provider in the 60th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$202,736
Medicare patients
743
Services billed
2,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$141,487
XolairOmalizumab46$121,987
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr109$72,818
Dupixent PenDupilumab12$59,532
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$58,306
Spiriva RespimatTiotropium Bromide44$46,984
Advair HfaFluticasone Propion/Salmeterol61$46,594
Spiriva HandihalerTiotropium Bromide38$39,216
SymbicortBudesonide/Formoterol Fumarate99$38,888
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$34,762
Incruse ElliptaUmeclidinium Bromide59$31,155
Combivent RespimatIpratropium/Albuterol Sulfate27$16,209
Breo ElliptaFluticasone/Vilanterol26$13,848
DuleraMometasone/Formoterol22$10,402
Pirfenidone14$9,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$20$259,308300 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$146$121,499119 claims
AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere$229$82,101154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →